Neuroscience research, therapies and partnerships in Virginia: Forming a new collaborative network to take on the challenge of our generation and those to come
Virginia and national experts will describe the vast and deep neuroscience research ongoing in Virginia universities, research institutions, health care systems and companies. They will share plans underway for growing a statewide neuroscience collaboration to align and coordinate strengths, to build important infrastructure, to pursue major research funding, to expand existing university-commercial partnerships and to develop new ones. They will describe a statewide three-university research collaboration with a major pharmaceutical company that is preparing to get underway, focused on a devastating neurodegenerative disease – ALS.
Part 1) Virginia Neuroscience Initiative
Michael Friedlander, Executive Director of the Virginia Tech Carilion Research Institute and Senior Dean for Research of the Virginia Tech Carilion School of Medicine; Jerome Strauss, Dean, VCU School Of Medicine; George Bloom, Professor, UVa Dept. of Biology; and Giorgio Ascoli, Director Center for Neural Informatics, Structure and Plasticity Molecular Neuroscience Dept. Krasnow Institute for Advanced Study, George Mason University
Leaders from Virginia Tech, Virginia Commonwealth University and the University of Virginia will share the vision and emerging plan that has been developed for coordinating and advancing the state’s excellence in neuroscience research through interactive partnerships between academic institutions, state government and industry. The goals are to catalyze the Commonwealth’s ascendance to a position of high national/global identity in the various sectors of brain research spanning healthcare, human performance, intelligent systems, medical devices, pharmaceuticals, data analytics and behavior. This program will provide a unique series of platforms for collaborative research between universities and institutions that coordinates with the state’s bioscience initiatives and provides a highly attractive partner for industry partners within the state and nation/worldwide.
Part 2) Collaboration with three Virginia research universities and big pharma to achieve breakthroughs in diagnostics and therapies for ALS.
Michael Friedlander, John Dunlop, VP and Global Head of Neurosciences at Astra Zeneca
Plans for a cooperative multi-Virginia university – corporate - state research initiative that brings a series of complementary research expertise and technologies together to address a major unmet national need in addressing one of the most devastating diseases – ALS, will be discussed. Laboratory scientists, clinicians and physician scientists, working closely with a major pharmaceutical company, Astra Zeneca and the Catalyst have developed a highly complementary approach to develop an entirely new approach to investigating potential new therapeutic approaches to ALS. Building on an established model that has succeeded with other universities and Astra Zeneca throughout North America, the team is coordinating a major new effort that brings the particular strengths of the multiple universities and the pharmaceutical industry to bear on this major health challenge.